If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A German University is searching a licensing partner for a newly developed class of Antibiotics against Gram-positive bacteria. Among them are some of the most dangerous pathogens for humans. It can be applied as an antibiotic or as a probiotic. Advantages of this new class are very rapid killing of pathogenic bacteria, low toxicity and an assumed targeting of structures, so far not covered by established antibiotics.
A German Research Group of a University has identified a new class of Antibiotics, showing extraordinary effects in animal models against highly-resistant bacteria, called Gram-positive Bacteria.
Among Gram-positive bacteria are some of the most dangerous pathogens for humans. Especially Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for a high percentage of hospital-acquired deadly infections, because of its resistance against common Antibiotics. The new found antibiotic class offers the possibility of developing new pharmaceutically applicable antibiotics.
On the other side, the newly identified naturally human-associated bacterial antibiotic producer strain (S. lugdunensis IVK28 wild type) could be applied as a probiotic cure before patients enter hospital. This could avoid costly decolonization of human commensal bacteria before surgery. Also it could replace usual antibiotics and thus reduce the hospitalization duration.
The antibiotic producer strain is applicable in human medicine but also in veterinary medicine against a broad range of Gram-positive bacteria. A patent application covering the chemical structures, the genetic background of the producer strain, the bioactivity of the new substances and their synthesis has been filed.
The University is looking for a licensing partner to take the antibiotic and/or antibiotic producer strain to a new medicine. Ideally this is a pharmaceutical company with experiences in the development of marketable medications.
- Very rapid killing of pathogenic bacteria even in the non-growing state. Application of 1 microgram/milliliter (MIC) leads to complete killing of bacteria in vitro.
- Efficiency of the pure compound already shown in a topical mouse model
- Low toxicity: First data point to a low cytotoxic potential against human cells.
- Preliminary data suggest, that molecular target might be a biochemical structure so far not targeted by established antibiotics.
Patent application filed, priority date 2015-03-23
Type of Partner: Industrial partner
Activity of Partner: Pharmaceutical company
Role of Partner: Licensing of the antibiotic substance for the development of a marketable product.